BACKGROUND/AIMS: During the last two decades, hundreds of reports have detailed putative prognostic and predictive biomarkers for colorectal cancer (CRC). However, the majority of these studies have been small and retrospective, reporting results that are highly likely to represent false positives. Consequently, their relevance to clinical practice requires definition. METHODS: Review of published literature on CRC biomarkers, focusing on early-stage disease. RESULTS: Although most putative biomarkers have failed to be validated in subsequent studies, level I evidence now indicates that tumour microsatellite instability can be used to identify a cohort of patients with stage IIA disease at low risk of relapse who can be spared adjuvant chemotherapy. Emerging data suggest that gene expression arrays may have a role in selecting patients with stage IIA disease and mismatch repair-proficient tumours for chemotherapy following tumour resection. CONCLUSION: Despite the profusion of biomarker literature, only mismatch repair status can be recommended as routine in current clinical practice. High-quality, adequately powered studies are essential to accurately define the utility of existing and putative biomarkers, and to support their rational application in the clinic.
BACKGROUND/AIMS: During the last two decades, hundreds of reports have detailed putative prognostic and predictive biomarkers for colorectal cancer (CRC). However, the majority of these studies have been small and retrospective, reporting results that are highly likely to represent false positives. Consequently, their relevance to clinical practice requires definition. METHODS: Review of published literature on CRC biomarkers, focusing on early-stage disease. RESULTS: Although most putative biomarkers have failed to be validated in subsequent studies, level I evidence now indicates that tumour microsatellite instability can be used to identify a cohort of patients with stage IIA disease at low risk of relapse who can be spared adjuvant chemotherapy. Emerging data suggest that gene expression arrays may have a role in selecting patients with stage IIA disease and mismatch repair-proficient tumours for chemotherapy following tumour resection. CONCLUSION: Despite the profusion of biomarker literature, only mismatch repair status can be recommended as routine in current clinical practice. High-quality, adequately powered studies are essential to accurately define the utility of existing and putative biomarkers, and to support their rational application in the clinic.
Authors: Scott Kopetz; Josep Tabernero; Robert Rosenberg; Zhi-Qin Jiang; Víctor Moreno; Thomas Bachleitner-Hofmann; Giovanni Lanza; Lisette Stork-Sloots; Dipen Maru; Iris Simon; Gabriel Capellà; Ramon Salazar Journal: Oncologist Date: 2015-01-05
Authors: David Church; Rachel Kerr; Enric Domingo; Dan Rosmarin; Claire Palles; Kevin Maskell; Ian Tomlinson; David Kerr Journal: Nat Rev Cancer Date: 2014-05-15 Impact factor: 60.716
Authors: Tavonna D Kako; Maahum Z Kamal; Jhalak Dholakia; Carly B Scalise; Rebecca C Arend Journal: Int J Clin Oncol Date: 2022-01-17 Impact factor: 3.402
Authors: Eric Le Balc'h; Nathalie Grandin; Marie-Véronique Demattei; Serge Guyétant; Anne Tallet; Jean-Christophe Pagès; Mehdi Ouaissi; Thierry Lecomte; Michel Charbonneau Journal: Int J Mol Sci Date: 2017-08-29 Impact factor: 5.923